01336 Overview

FTSE China Index Series Review: FTSE Russell has released the results of the FTSE China Index Series quarterly review for 1Q26, highlighting its significance as a benchmark for the Chinese equity market, with nearly 60% of globally issued ETFs tracking a FTSE China index.

Index Additions and Removals: The FTSE China A50 Index will include new stocks such as CHINA CSSC, TFC, and WANHUA CHEM, while removing EVERBRIGHT BANK, CRRC, and SHANXI FEN WINE.

FTSE China 50 Index Changes: The FTSE China 50 Index will add NCI and WEICHAI POWER, and remove MINSHENG BANK and ZTE, with details on short selling ratios provided for each stock.

Market Data Notes: The article includes a note that Hong Kong stock quotes are delayed by at least 15 minutes, and short selling data is current as of March 4, 2026.

Market Overview: The Hong Kong bourse opened lower, with the Hang Seng Index (HSI) dropping 509 points or 1.9% to 26,572, amid a turnover of HKD124.419 billion.

Pharmaceutical Sector Decline: Pharmaceutical stocks were the biggest losers, with notable declines in HANSOH PHARMA, SINO BIOPHARM, and CSPC PHARMA, all experiencing significant short selling.

Insurance Sector Struggles: Chinese insurers faced pressure, with major companies like CHINA LIFE and PING AN seeing substantial losses, contributing to a broader decline in the financial sector.

AI Stocks Recovery: Three AI-related semi-IPOs rebounded after previous losses, with MINIMAX-WP, KNOWLEDGE ATLAS, and HAIZHI TECH GP all posting gains and increased trading volumes.

Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.

Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".

Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.

Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.

Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.

Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.

Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.

Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.

Citi's Negative Catalyst Watch on CPIC: Citi has initiated a 90-day negative catalyst watch on CPIC (02601.HK), predicting that its FY25 results will underperform compared to peers, with a projected 28% growth in new life insurance business.

Comparative Performance Expectations: The anticipated combined operating ratio for CPIC in FY25 is 98.0%, which is less favorable than major competitors like PICC GROUP and PING AN, whose ratios are forecasted at 97.3% and 97.1%, respectively.

Earnings Growth Projections: CPIC's projected 16% year-over-year earnings increase for FY25 is significantly lower than the expected growth rates of its competitors, such as CHINA TAIPING at 220% and CHINA LIFE at 47%.

Citi's Rating and Target Price: Despite the negative outlook, Citi has rated CPIC as a Buy and set a target price of HKD 44.9.

Citi Research Report: Citi Research has placed NCI (01336.HK) under a 90-day downside catalyst watch, anticipating negative impacts from weak growth stock performance in the A-share market during 4Q25 and 1Q26.

Stock Performance: NCI's stock has seen a slight increase of +1.050 (+1.799%), with short selling amounting to $14.64 million and a short selling ratio of 13.303%.

Broker Rating: The broker has rated NCI as Neutral, setting a target price of $62.3 for the stock.

Market Context: The report highlights NCI's higher exposure to public equity, which may lead to greater vulnerability in the anticipated market downturn.